KR960703843A - 아실페닐글리신 유도체 및 그 화합물을 유효성분으로 하는, 콜라게나제 활성증진에 기인한 질환의 예방 및 치료 제(acylphenylglycine derivative and preventive and remedy for diseases caused by increased collagenase activity containing said compound as active ingredient) - Google Patents

아실페닐글리신 유도체 및 그 화합물을 유효성분으로 하는, 콜라게나제 활성증진에 기인한 질환의 예방 및 치료 제(acylphenylglycine derivative and preventive and remedy for diseases caused by increased collagenase activity containing said compound as active ingredient)

Info

Publication number
KR960703843A
KR960703843A KR1019960700667A KR19960700667A KR960703843A KR 960703843 A KR960703843 A KR 960703843A KR 1019960700667 A KR1019960700667 A KR 1019960700667A KR 19960700667 A KR19960700667 A KR 19960700667A KR 960703843 A KR960703843 A KR 960703843A
Authority
KR
South Korea
Prior art keywords
remedy
active ingredient
hydrogen atom
acylphenylglycine
preventive
Prior art date
Application number
KR1019960700667A
Other languages
English (en)
Other versions
KR100312097B1 (ko
Inventor
료이치 히라야마
다카히로 츠키다
미노루 야마모토
쇼지 이케다
후미오 사카모토
유지 오바타
고노미 마츠오
Original Assignee
이시하라 소이치
가네보 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이시하라 소이치, 가네보 가부시키가이샤 filed Critical 이시하라 소이치
Publication of KR960703843A publication Critical patent/KR960703843A/ko
Application granted granted Critical
Publication of KR100312097B1 publication Critical patent/KR100312097B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

하기식(Ⅰ)
(식중, R1은 수소원자, 메틸기, 메틸아미노메틸기 또는 모르폴리노메틸기를 나타내고, R2는 수소원자, 수산기, 플로오르원자 또는 탄소수 1∼4의 직쇄 또는 분지쇄상 알킬기를 나타내고, R3은 탄소수 1∼4의 직쇄 또는 분지쇄상 알킬기를 나타낸다)로 표시되는 아실페닐글리신 유도체 또는 약학적으로 허용되는 그것의 염 및 이들을 유효성분으로 하는, 콜라게나제 활성증진에 기인하는 질환의 예방 및 치료 제.
화합물(Ⅰ) 또는 약학적으로 허용되는 그것의 염은 생체에 투여한 후, 장시간에 걸쳐 혈중에서 강한 콜라게나제 저해활성을 유지하고, 콜라게나제 활성의 증진에 기인한다고 생각되는 각종 질환의 치료제로서 유용하다.

Description

아실페닐글리신 유도체 및 그 화합물을 유효성분으로 하는, 콜라게나제 활성증진에 기인한 질환의 예방 및 치료 제(ACYLPHENYLGLYCINE DERIVATIVE AND PREVENTIVE AND REMEDY FOR DISEASES CAUSED BY INCREASED COLLAGENASE ACTIVITY CONTAINING SAID COMPOUND AS ACTIVE INGREDIENT)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 하기식(Ⅰ)
    (식중, R1은 수소원자, 메틸기, 메틸아미노메틸기 또는 모르폴리노메틸기를 나타내고, R2는 수소원자, 수산기, 플로오르원자 또는 탄소수 1∼4의 직쇄 또는 분지쇄상 알킬기를 나타내고, R3은 탄소수 1∼4의 직쇄 또는 분지쇄상 알킬기를 나타낸다)로 표시되는 것을 특징으로 하는, 아실페닐글리신 유도체 또는 약학적으로 허용되는 그것의 염.
  2. 제1항에 있어서, R1및 R3이 모두 메틸기이고, R2가 수소원자인 것을 특징으로 하는, 아실페닐글리신 유도체 또는 약학적으로 허용되는 그것의 염.
  3. 제1항 또는 제2항에 의한 아실페닐글리신 유도체 또는 약학적으로 허용되는 그것의 염을 유효성분으로 하는, 콜라게나제 활성증진에 기인하는 질환의 예방 및 치료 제.
  4. 제3항에 있어서, 콜라게나제 활성증진에 기인한 질환이 관절질환 또는 골흡수질환인 것을 특징으로 하는 예방 및 치료 제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960700667A 1993-08-09 1994-08-03 아실페닐글리신 유도체 및 그 화합물을 유효성분으로하는,콜라게나제활성증진에기인한질환의예방및치료제 KR100312097B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP21812493 1993-08-09
JP93-218124 1993-08-09
PCT/JP1994/001284 WO1995004715A1 (fr) 1993-08-09 1994-08-03 Derive d'acylphenylglycine et agent preventif et curatif, concernant des maladies causees par une activite collagenase accrue, contenant un tel compose comme ingredient actif

Publications (2)

Publication Number Publication Date
KR960703843A true KR960703843A (ko) 1996-08-31
KR100312097B1 KR100312097B1 (ko) 2002-11-13

Family

ID=16715014

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960700667A KR100312097B1 (ko) 1993-08-09 1994-08-03 아실페닐글리신 유도체 및 그 화합물을 유효성분으로하는,콜라게나제활성증진에기인한질환의예방및치료제

Country Status (10)

Country Link
US (1) US5795891A (ko)
EP (1) EP0712838B1 (ko)
KR (1) KR100312097B1 (ko)
CN (1) CN1038583C (ko)
AT (1) ATE172959T1 (ko)
DE (1) DE69414396T2 (ko)
DK (1) DK0712838T3 (ko)
ES (1) ES2123808T3 (ko)
TW (1) TW280810B (ko)
WO (1) WO1995004715A1 (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501737D0 (en) * 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
HUP9903863A3 (en) 1995-11-23 2000-11-28 British Biotech Pharm Metalloproteinase inhibitors
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
CN1060804C (zh) * 1997-03-17 2001-01-17 中国科学院微生物研究所 Iv型胶原酶特异性人源基因工程抗体
WO2001052891A1 (fr) * 2000-01-20 2001-07-26 Nippon Organon K. K. Inhibiteurs d'invasion plasmodiale dans des erythrocytes
EP3860608A1 (en) 2018-10-04 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas
CN110554118A (zh) * 2019-10-15 2019-12-10 宁夏师范学院 一种检测尿液中萘酚含量的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
WO1992022523A2 (en) * 1991-06-14 1992-12-23 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor

Also Published As

Publication number Publication date
US5795891A (en) 1998-08-18
DE69414396D1 (de) 1998-12-10
TW280810B (ko) 1996-07-11
CN1038583C (zh) 1998-06-03
EP0712838A4 (en) 1996-03-19
WO1995004715A1 (fr) 1995-02-16
CN1133034A (zh) 1996-10-09
DE69414396T2 (de) 1999-07-15
DK0712838T3 (da) 1999-07-19
ES2123808T3 (es) 1999-01-16
KR100312097B1 (ko) 2002-11-13
ATE172959T1 (de) 1998-11-15
EP0712838B1 (en) 1998-11-04
EP0712838A1 (en) 1996-05-22

Similar Documents

Publication Publication Date Title
LU91943I2 (fr) Tafluprost et ses dérivés pharmaceutiquement acceptables (SAFLUTAN®)
KR890011601A (ko) (사이클로알킬아미노)메틸렌비스(포스폰산)및 활성성분으로서 이를 함유한 의약
KR950000728A (ko) 포스포네이트 뉴클레오티드 에스테르 유도체
KR950016745A (ko) 생리증상의 치료방법 및 이를 위한 조성물
KR890016966A (ko) 신규 항바이러스제
KR950016732A (ko) 피부 및 질의 위축 억제방법
KR970074765A (ko) 비타민 d₃ 동족체
KR950010892A (ko) 자궁 섬유증 억제 방법
KR950010889A (ko) 혈관형성 및 혈관형성성 질병을 억제하는 방법
ES2163425T3 (es) Uso de raloxifeno y de sus analogos para la fabricacion de un medicamento para el tratamiento de la ateroesclerosis y la enfermedad cardiaca isquemica.
KR950000663A (ko) 트리테르펜 유도체 및 이를 함유하는 엔도텔린-수용체 길항물질
KR910004191A (ko) 신질환치료제
KR950703527A (ko) 프로스타글란딘 유도체
KR970074763A (ko) 불소화된 비타민 d₃ 유사체
KR960703843A (ko) 아실페닐글리신 유도체 및 그 화합물을 유효성분으로 하는, 콜라게나제 활성증진에 기인한 질환의 예방 및 치료 제(acylphenylglycine derivative and preventive and remedy for diseases caused by increased collagenase activity containing said compound as active ingredient)
KR950016760A (ko) 치질 치료제
EP0955046A3 (en) Amino acid derivatives and anti-inflammatory agents
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
KR920007995A (ko) 벤즈아미드 유도체
KR890011868A (ko) 간질환 치료제 및 피페라진 유도체
DE3476160D1 (en) Derivatives of benzoic acid for use as a medicament and use of these derivatives as conserving or disinfecting agent
KR970704685A (ko) 신경이완제로서 유용한 N-치환 아자비시클로헵탄 유도체(N-Substituted Azabicycloheptane Derivatives Useful as Neuroleptics)
KR950032194A (ko) 신규푸린유도체 및 그 약학적으로 허용되는 염
RS50033B (sr) Derivati etansulfonil-piperidina
KR970064604A (ko) 벤조피란 유도체 및 그의 심장질환 치료제로서의 용도

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee